Irreversible aromatase inactivation: treatment for breast cancer.
Third-generation aromatase inhibitors extend treatment options for postmenopausal breast cancer patients refractory to initial antioestrogen therapy. This article reviews advances and recent developments in hormonal therapy, focusing in particular on exemestane, a new class of aromatase inactivator.
Johnston
S R
SR
Royal Marsden Hospital, London.
D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; C056516:exemestane